In 2025, BMKDF achieved transformative progress in early cancer detection. The company doubled its laboratory throughput capacity and expanded its technical team by 40%, including hires in molecular biology and AI/ML data science. BMKDF submitted ISO 15189 certification documents in December, a critical step toward U.S. CLIA and CAP accreditation. Clinically, the firm completed Canada’s largest lung cancer diagnostic study with over 7,000 patients and was chosen as the exclusive diagnostic partner for the 10,000-patient HANSE trial—the largest prospective lung cancer study since 2013. Scientific output included more than six peer-reviewed publications and an industry innovation prize for its metabolomics and AI-driven platform. On the funding front, BMKDF raised $4.5 million in a challenging small-cap environment, secured collaborative grants from the Manitoba Lung Association and NRC Horizon Europe, and obtained municipal research support in Quebec.

On December 30, 2025, BMKDF appointed technology investor and AI strategist James Lavender to its board of directors following shareholder approval at the annual general meeting. Lavender led a major insider financing round in March 2025 and brings deep expertise in scaling data-driven platforms and forging high-level U.S. market alliances. His network includes state health agencies and strategic investment groups, positioning BMKDF to finalize its CLIA/CAP application and negotiate reimbursement pathways with screening centers and payors. Management emphasizes that his software development and enterprise sales background will be instrumental as BMKDF commercializes its ISO-certified laboratory services and expands distribution through major clinic chains.